Real‐Practice Analysis of Potential Antibiotic Interactions in Patients Treated With Immune Checkpoint Inhibitors: An Observational Study From an Italian Referral Cancer Center
Authors:
- Alberto RussiARAlberto Russi
- Camilla SaranCSCamilla Saran
- Giulia ZanchettaGZGiulia Zanchetta
- Giorgia ZorzettoGZGiorgia Zorzetto
- Giovanna CrivellaroGCGiovanna Crivellaro
- Marco MaruzzoMMMarco Maruzzo
- Giulia PaselloGPGiulia Pasello
- Alessio FabozziAFAlessio Fabozzi
- Chiara De ToniCTChiara De Toni
- Carola CenziCCCarola Cenzi
- Elena BertiEBElena Berti
- Silvia CognolatoSCSilvia Cognolato
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Abstract
Purpose: Inappropriate use of antibiotics contributes to the increase in antimicrobial resistance with negative health safety implications. Global health organizations have promoted projects to improve proper and rational use of antibiotics. Recent studies show how antibiotics can also influence the efficacy of immune checkpoint inhibitors (ICIs) treatment in cancer patients. This work analyzes the impact of concomitant antibiotic therapy in patients affected by skin, lung, and kidney cancer, who started immunotherapy in 2020‐2021 at Veneto Institute of Oncology IRCCS. The aim of this study is to evaluate clinical outcomes, treatment efficacy, discontinuation causes, and occurrence of adverse drug reactions in cancer patients treated with ICIs. Methods: Data from the real‐world retrospective study were extracted from Territorial Pharmaceutical Care databases, medical records, and the AIFA registry. A descriptive analysis of the study population was performed, as well as of patient outcomes in terms of progression‐free survival (PFS) and overall survival (OS). Results: A total of 239 subjects affected by kidney (8%), lung (48%), and skin (44%) cancer were enrolled; of these, 50%, 32%, 9%, and 9% were treated with single‐agent nivolumab, pembrolizumab, atezolizumab, and cemiplimab, respectively. A total of 119 patients received concomitant antibiotic therapy. Median OS was 8.8 months (95% CI: 5.02–11.8) and 31.05 months (95% CI: 24.81–NA) in subjects with high and low antibiotic exposure, respectively. Multivariate subgroup analysis confirmed that high antibiotic exposure is an unfavorable factor also for median PFS. Conclusion: A prolonged exposure to antibiotics correlates with unfavorable outcomes in cancer patients undergoing concomitant immunotherapy. Thus, managing antibiotic exposure is fundamental for optimizing ICI treatment.Keywords
This publication has 32 references indexed in Scilit:
- Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse EventsClinical Genitourinary Cancer, 2023
- Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR StudyTargeted Oncology, 2022
- SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)Clinical and Translational Oncology, 2022
- Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective studyCancer Immunology, Immunotherapy, 2021
- Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinomaInternational Urology and Nephrology, 2021
- Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancerCancer Treatment Reviews, 2020
- Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trialsAnnals of Oncology, 2020
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With CancerJAMA Oncology, 2020
- Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunitiesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2017
- The development and evaluation of an oncological palliative care deprescribing guideline: the ‘OncPal deprescribing guideline’Supportive Care in Cancer, 2014